IMC.AX - Immuron Limited

ASX - ASX Delayed Price. Currency in AUD
0.24
0.00 (0.00%)
At close: 3:56PM AEDT
Stock chart is not supported by your current browser
Previous Close0.24
Open0.24
Bid0.00 x 1888800
Ask0.00 x 10722300
Day's Range0.23 - 0.24
52 Week Range0.14 - 0.70
Volume306,181
Avg. Volume189,922
Market Cap31.516M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-0.06
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.13
  • GlobeNewswire8 days ago

    CEO to Present on US Investor TV Show and at Biotech Conference

    MELBOURNE, Australia, Jan. 10, 2018-- Immuron Limited is pleased to advise investors that CEO Dr Jerry Kanellos, was interviewed on The RedChip Money Report US television program. The interview will air ...

  • GlobeNewswirelast month

    Immuron to Present at RedChip’s Global Online Growth Conference

    MELBOURNE, Australia, Dec. 06, 2017-- Immuron Limited wishes to advise investors that CEO Dr Jerry Kanellos is scheduled to present at RedChip’ s Global Online Growth Conference on Wednesday, December ...

  • GlobeNewswire2 months ago

    Van Leeuwenhoeck Institute Updates Immuron Research Coverage

    MELBOURNE, Australia, Nov. 22, 2017-- Immuron Limited wishes to advise investors that Van Leeuwenhoeck Institute, a prominent European and US-based Life Sciences Research and Analyst firm, has published ...

  • GlobeNewswire2 months ago

    Immuron Granted US Patent for NASH Treatment

    MELBOURNE, Australia, Nov. 15, 2017-- Immuron Limited, an Australian microbiome biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the treatment of gut-mediated ...

  • GlobeNewswire2 months ago

    Immuron Successfully Completes NASH Phase II Clinical Study Milestone

    MELBOURNE, Australia, Nov. 09, 2017-- Immuron Limited, an Australian microbiome biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the treatment of gut-mediated ...

  • GlobeNewswire2 months ago

    Travelan Experiences Strong Q1 FY2018 Sales Growth

    Significant growth of sales for Immuron’ s over-the-counter supplement Travelan ® for Q1 2018 compared to Q1 2017 Travelan ® US experienced a 197% increase in sales compared to Q1 2017 Travelan ® Australia ...

  • U.S. exchanges set for highest number of Asian IPOs since 2010
    Reuters3 months ago

    U.S. exchanges set for highest number of Asian IPOs since 2010

    U.S. exchanges are set to record their busiest year for IPOs from Asian firms since 2010 and may sustain the pace in 2018, as startups from Taiwan, Singapore, Indonesia and Vietnam join a flurry of Chinese firms that have already listed in the country. Chinese issuers have dominated U.S. IPO activity for several years, but Nasdaq and rival New York Stock Exchange (NYSE) have been increasingly targeting firms from fast-growing Southeast Asian economies and startups from Japan and Australia to counter their dependence on mainland companies.